CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Repayments of Other Debt
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Repayments of Other Debt of $375.21 million for the 6-month period ending 2016-06-25, per its 10-Q filed 2016-08-03.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfOtherDebt · last filed 2016-08-03
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayments of other debt for the quarter ending 2016-06-25 was $325.80M, a 17.36% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayments of other debt for the quarter ending 2016-03-26 was $49.41M, a 108.67% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayments of other debt for the quarter ending 2015-12-26 was $26.28M, a 57.68% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayments of other debt for the quarter ending 2015-09-26 was $89.77M, a 163.81% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayments of other debt for fiscal 2015 was $417.33M, a 114.53% increase from fiscal 2014.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayments of other debt for fiscal 2014 was $194.54M, a 62.83% decline from fiscal 2013.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayments of other debt for fiscal 2013 was $523.30M, a 272.86% increase from fiscal 2012.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. repayments of other debt for fiscal 2012 was $140.35M, a 44.52% decline from fiscal 2011.
| Period end | Repayments of Other Debt 3 month | Repayments of Other Debt 6 month | Repayments of Other Debt 9 month | Repayments of Other Debt 12 month |
|---|---|---|---|---|
| 2016-06-25 | $325.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $375.21M 10-Q · filed 2016-08-03 | $401.49M derived: sum of 3 quarters · filed 2016-08-03 | $491.26M derived: sum of 4 quarters · filed 2016-08-03 |
| 2016-03-26 | $49.41M 10-Q · filed 2016-05-04 | $75.69M derived: sum of 2 quarters · filed 2016-05-04 | $165.46M derived: sum of 3 quarters · filed 2016-05-04 | $443.06M derived: sum of 4 quarters · filed 2016-08-03 |
| 2015-12-26 | $26.28M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $116.05M derived: sum of 2 quarters · filed 2016-02-12 | $393.65M derived: sum of 3 quarters · filed 2016-08-03 | $417.33M 10-K · filed 2016-02-12 |
| 2015-09-26 | $89.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $367.37M derived: sum of 2 quarters · filed 2016-08-03 | $391.05M 10-Q · filed 2015-11-04 | $453.15M derived: sum of 4 quarters · filed 2016-08-03 |
| 2015-06-27 | $277.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $301.28M 10-Q · filed 2016-08-03 | $363.39M derived: sum of 3 quarters · filed 2016-08-03 | $397.42M derived: sum of 4 quarters · filed 2016-08-03 |
| 2015-03-28 | $23.68M 10-Q · filed 2016-05-04 | $85.78M derived: sum of 2 quarters · filed 2016-05-04 | $119.81M derived: sum of 3 quarters · filed 2016-05-04 | $145.63M derived: sum of 4 quarters · filed 2016-05-04 |
| 2014-12-27 | $62.10M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $96.13M derived: sum of 2 quarters · filed 2016-02-12 | $121.95M derived: sum of 3 quarters · filed 2016-02-12 | $194.54M 10-K · filed 2016-02-12 |
| 2014-09-27 | $34.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $59.84M derived: sum of 2 quarters · filed 2015-11-04 | $132.43M 10-Q · filed 2015-11-04 | $153.49M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-28 | $25.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-30 | $98.40M 10-Q · filed 2015-07-30 | $119.47M derived: sum of 3 quarters · filed 2016-02-12 | $160.52M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-29 | $72.59M 10-Q · filed 2015-04-30 | $93.65M derived: sum of 2 quarters · filed 2016-02-12 | $134.71M derived: sum of 3 quarters · filed 2016-02-12 | $540.99M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-28 | $21.06M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $62.12M derived: sum of 2 quarters · filed 2016-02-12 | $468.40M derived: sum of 3 quarters · filed 2016-02-12 | $523.30M 10-K · filed 2016-02-12 |
| 2013-09-28 | $41.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $447.34M derived: sum of 2 quarters · filed 2014-10-30 | $502.24M 10-Q · filed 2014-10-30 | $529.86M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-06-29 | $406.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $461.18M 10-Q · filed 2014-08-07 | $488.80M derived: sum of 3 quarters · filed 2015-02-17 | $525.18M derived: sum of 4 quarters · filed 2015-02-17 |
| 2013-03-30 | $54.90M 10-Q · filed 2014-04-30 | $82.52M derived: sum of 2 quarters · filed 2015-02-17 | $118.89M derived: sum of 3 quarters · filed 2015-02-17 | $148.68M derived: sum of 4 quarters · filed 2015-02-17 |
| 2012-12-29 | $27.62M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $63.99M derived: sum of 2 quarters · filed 2015-02-17 | $93.78M derived: sum of 3 quarters · filed 2015-02-17 | $140.35M 10-K · filed 2015-02-17 |
| 2012-09-29 | $36.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $66.17M derived: sum of 2 quarters · filed 2013-10-30 | $112.73M 10-Q · filed 2013-10-30 | $151.40M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $29.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $76.36M 10-Q · filed 2013-07-31 | $115.02M derived: sum of 3 quarters · filed 2014-02-25 | $247.31M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $46.57M 10-Q · filed 2013-05-08 | $85.23M derived: sum of 2 quarters · filed 2014-02-25 | $217.52M derived: sum of 3 quarters · filed 2014-02-25 | $289.76M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $38.67M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $170.95M derived: sum of 2 quarters · filed 2014-02-25 | $243.20M derived: sum of 3 quarters · filed 2014-02-25 | $252.97M 10-K · filed 2014-02-25 |
| 2011-09-24 | $132.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $204.53M derived: sum of 2 quarters · filed 2012-11-01 | $214.30M 10-Q · filed 2012-11-01 | $231.05M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-25 | $72.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $82.01M 10-Q · filed 2012-08-07 | $98.77M derived: sum of 3 quarters · filed 2013-02-27 | $399.82M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-26 | $9.77M 10-Q · filed 2012-05-04 | $26.52M derived: sum of 2 quarters · filed 2013-02-27 | $327.57M derived: sum of 3 quarters · filed 2013-02-27 | $368.62M derived: sum of 4 quarters · filed 2013-02-27 |
| 2010-12-25 | $16.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $317.80M derived: sum of 2 quarters · filed 2013-02-27 | $358.85M derived: sum of 3 quarters · filed 2013-02-27 | $381.54M 10-K · filed 2013-02-27 |
| 2010-09-25 | $301.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $342.10M derived: sum of 2 quarters · filed 2011-11-02 | $364.78M 10-Q · filed 2011-11-02 | $373.41M derived: sum of 4 quarters · filed 2012-02-27 |
| 2010-06-26 | $41.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | $63.73M 10-Q · filed 2011-08-03 | $72.36M derived: sum of 3 quarters · filed 2012-02-27 | $100.54M derived: sum of 4 quarters · filed 2012-02-27 |
| 2010-03-27 | $22.68M 10-Q · filed 2011-05-04 | $31.31M derived: sum of 2 quarters · filed 2012-02-27 | $59.49M derived: sum of 3 quarters · filed 2012-02-27 | |
| 2009-12-26 | $8.63M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27 | $36.81M derived: sum of 2 quarters · filed 2012-02-27 | $54.13M 10-K · filed 2012-02-27 | |
| 2009-09-26 | $28.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | $45.50M 10-Q · filed 2010-11-04 | ||
| 2009-06-27 | $17.32M 10-Q · filed 2010-08-03 | |||
| 2008-12-27 | $36.54M 10-K · filed 2011-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |